Dana-Farber Cancer Institute
@danafarber.bsky.social
A leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | http://dana-farber.org
Appts: 877-442-3324 | http://dana-farber.org
Jacqueline Garcia, MD, is exploring ongoing clinical research to test novel triplet therapies for safety and efficacy with a precision medicine approach for patients with acute myeloid leukemia. Explore the latest updates: bit.ly/3LmZEUC
November 25, 2025 at 5:30 PM
Jacqueline Garcia, MD, is exploring ongoing clinical research to test novel triplet therapies for safety and efficacy with a precision medicine approach for patients with acute myeloid leukemia. Explore the latest updates: bit.ly/3LmZEUC
Please join us in congratulating Christopher Lathan, MD, MS, MPH, as the recipient of this year's Arthur T. Skarin Award on behalf of the Board of Directors of the Massachusetts Society of Clinical Oncologists (MSCO).
November 23, 2025 at 2:00 PM
Please join us in congratulating Christopher Lathan, MD, MS, MPH, as the recipient of this year's Arthur T. Skarin Award on behalf of the Board of Directors of the Massachusetts Society of Clinical Oncologists (MSCO).
The @fda.gov approved sevabertinib for HER2-mutant non-small-cell lung cancer, supported by a multi-year research collaboration with colleagues at the @broadinstitute.org. Learn more: bit.ly/49Q2vjd
Dana-Farber research supports FDA approval of sevabertinib for HER2-mutant lung cancer | Dana-Farber Cancer Institute
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy. The approval reflects a multi-year collaboration led by Dana-Farber Cancer Institute investigators, working closely with colleagues at the Broad Institute.
www.dana-farber.org
November 21, 2025 at 2:30 PM
The @fda.gov approved sevabertinib for HER2-mutant non-small-cell lung cancer, supported by a multi-year research collaboration with colleagues at the @broadinstitute.org. Learn more: bit.ly/49Q2vjd
Join Anthony Fauci, MD, and Navid Madani, PhD, on December 2 for the Science Health Education (SHE) Center’s upcoming conversation. Please register and submit questions here: bit.ly/4rdeTzY
November 20, 2025 at 1:00 PM
Join Anthony Fauci, MD, and Navid Madani, PhD, on December 2 for the Science Health Education (SHE) Center’s upcoming conversation. Please register and submit questions here: bit.ly/4rdeTzY
At yesterday’s #GlobeSummit2025, our President and CEO Benjamin L. Ebert, MD, PhD, joined Beth Israel Lahey Health and @massbio.bsky.social for an engaging conversation on Funding the Next Cure.
November 19, 2025 at 1:30 PM
At yesterday’s #GlobeSummit2025, our President and CEO Benjamin L. Ebert, MD, PhD, joined Beth Israel Lahey Health and @massbio.bsky.social for an engaging conversation on Funding the Next Cure.
Christopher Reilly, MD, and Vincent Ho, MD are optimizing how leukemia and stem cell transplant teams collaborate through a tandem consult model that promotes early alignment of treatment strategy and streamlines coordination of patient care. Learn more: bit.ly/47HNMnw
November 18, 2025 at 2:30 PM
Christopher Reilly, MD, and Vincent Ho, MD are optimizing how leukemia and stem cell transplant teams collaborate through a tandem consult model that promotes early alignment of treatment strategy and streamlines coordination of patient care. Learn more: bit.ly/47HNMnw
Pancreatic cancer has long been difficult to detect and treat – but researchers in the Hale Family Center for Pancreatic Cancer Research are working to change that through advances in early detection, RAS-targeted therapies, and immunotherapy. Learn more: bit.ly/4oUm0eH
Three Ways Research Could Improve Pancreatic Cancer Treatment
Published: November 3, 2025Pancreatic cancer has long been difficult to detect and treat. Dana-Farber experts in the Hale Family Center for Pancreatic Cancer Research, however, are working to change that with research efforts in three key areas that are poised to advance early detection, early intervention, and treatment of the disease. They presented these topics ... Read more
bit.ly
November 16, 2025 at 5:00 PM
Pancreatic cancer has long been difficult to detect and treat – but researchers in the Hale Family Center for Pancreatic Cancer Research are working to change that through advances in early detection, RAS-targeted therapies, and immunotherapy. Learn more: bit.ly/4oUm0eH
Congratulations to Eric Smith, MD, PhD, and Andrew Aguirre, MD, PhD, who are among recipients of the DeGregorio Family Foundation Michael F. Price Memorial Grant. Learn more: bit.ly/4p7qYF0
November 15, 2025 at 2:00 PM
Congratulations to Eric Smith, MD, PhD, and Andrew Aguirre, MD, PhD, who are among recipients of the DeGregorio Family Foundation Michael F. Price Memorial Grant. Learn more: bit.ly/4p7qYF0
We’re proud to partner with NeighborHealth to bring world-renowned cancer expertise closer to home for NeighborHealth patients, helping close persistent gaps in cancer diagnosis and treatment. Learn more: bit.ly/4nTTKYz
Dana-Farber and NeighborHealth Partner to Expand Cancer Care Access for Underserved Communities | Dana-Farber Cancer Institute
Dana-Farber Cancer Institute and NeighborHealth today announced the launch of a new partnership, bringing world-renowned cancer expertise directly to NeighborHealth patients to help close persistent gaps in cancer diagnosis and treatment.
bit.ly
November 13, 2025 at 6:50 PM
We’re proud to partner with NeighborHealth to bring world-renowned cancer expertise closer to home for NeighborHealth patients, helping close persistent gaps in cancer diagnosis and treatment. Learn more: bit.ly/4nTTKYz
@clarivate.com has recognized more than 35 Dana-Farber faculty members on the 2025 Highly Cited Researchers list for the significant and broad contributions they’ve demonstrated in their field of research. Congratulations to all! Learn more: bit.ly/4nTCwKX
Dana-Farber Cancer Institute faculty among world's most highly cited researchers | Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is proud to announce that 38 of its researchers have been named to the Highly Cited Researchers list of 2025, released today by the Institute for Scientific Information at Clarivate.
bit.ly
November 12, 2025 at 6:10 PM
@clarivate.com has recognized more than 35 Dana-Farber faculty members on the 2025 Highly Cited Researchers list for the significant and broad contributions they’ve demonstrated in their field of research. Congratulations to all! Learn more: bit.ly/4nTCwKX
This Veterans Day, @boston25news.com highlights the Sentinel Study – a clinical trial using multi-cancer early detection tests to support veterans, a population at increased risk. Learn more: bit.ly/3LAC9aE
Dana-Farber launches cancer detection trial for Veterans
Dana-Farber Cancer Institute is enrolling veterans in a clinical trial to help detect cancer.
bit.ly
November 11, 2025 at 8:55 PM
This Veterans Day, @boston25news.com highlights the Sentinel Study – a clinical trial using multi-cancer early detection tests to support veterans, a population at increased risk. Learn more: bit.ly/3LAC9aE
Menin inhibitors are a promising new class of drugs for acute leukemias. Richard Stone, MD, provides an update on our impact and ongoing clinical research efforts to advance menin inhibitor therapies for acute leukemias, aiming for effective and potentially all-oral treatments: bit.ly/4qL0b2S
November 11, 2025 at 4:00 PM
Menin inhibitors are a promising new class of drugs for acute leukemias. Richard Stone, MD, provides an update on our impact and ongoing clinical research efforts to advance menin inhibitor therapies for acute leukemias, aiming for effective and potentially all-oral treatments: bit.ly/4qL0b2S
During Pancreatic Cancer Awareness Month, we’re highlighting new research from Dana-Farber, @mit.edu, and the @broadinstitute.org revealing potential new ways to harness the immune system against pancreatic cancer. Learn more: bit.ly/3Wt0qBN
November 10, 2025 at 6:00 PM
During Pancreatic Cancer Awareness Month, we’re highlighting new research from Dana-Farber, @mit.edu, and the @broadinstitute.org revealing potential new ways to harness the immune system against pancreatic cancer. Learn more: bit.ly/3Wt0qBN
Congratulations to Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA), of our Connell and O'Reilly Families Cell Manipulation Core Facility and recipient of the AABB's 2025 President's Award for her extraordinary dedication and service.
November 7, 2025 at 2:30 PM
Congratulations to Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA), of our Connell and O'Reilly Families Cell Manipulation Core Facility and recipient of the AABB's 2025 President's Award for her extraordinary dedication and service.
New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org
Read more at bit.ly/4onnFJO
Read more at bit.ly/4onnFJO
November 6, 2025 at 7:30 PM
New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org
Read more at bit.ly/4onnFJO
Read more at bit.ly/4onnFJO
The @fda.gov approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Learn more: bit.ly/3WEexnN
November 5, 2025 at 1:30 PM
The @fda.gov approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Learn more: bit.ly/3WEexnN
What happens when targeted therapy meets radiation therapy? Learn about the exciting and innovative form of medicine called radioligand therapy: bit.ly/47vXrxy
November 3, 2025 at 11:00 PM
What happens when targeted therapy meets radiation therapy? Learn about the exciting and innovative form of medicine called radioligand therapy: bit.ly/47vXrxy
Dr. Vinayak Venkataraman of @danafarber.bsky.social spoke with @curetoday.bsky.social about how emerging second- and third-line therapeutic strategies and investigational agents may shift the standard of care for patients with GIST.
➡️ bit.ly/3LI7yry
➡️ bit.ly/3LI7yry
New Directions in Treatment for Patients With GIST | CURE
Emerging investigational agents may shift the current standard of care for patients with the rare sarcoma known as gastrointestinal stromal tumors.
bit.ly
November 3, 2025 at 7:45 PM
Dr. Vinayak Venkataraman of @danafarber.bsky.social spoke with @curetoday.bsky.social about how emerging second- and third-line therapeutic strategies and investigational agents may shift the standard of care for patients with GIST.
➡️ bit.ly/3LI7yry
➡️ bit.ly/3LI7yry
In a study published in the Journal of Pediatric Psychology, Eric Zhou, PhD, highlights Dana-Farber/Boston Children's Cancer and Blood Disorders Center's new "Sleep ALL Night" program, which aims to help children with leukemia sleep better during treatment. Read more: bit.ly/47NOhO0
Dana-Farber’s “Sleep ALL Night” Program Helps Children with Leukemia Sleep Better During Treatment | Dana-Farber Cancer Institute
Disrupted sleep is a common, often overlooked problem for pediatric patients being treated for acute lymphoblastic leukemia (ALL). To address this issue, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Institute created Sleep ALL Night—a program designed to protect children’s sleep during treatment.
bit.ly
November 1, 2025 at 1:00 PM
In a study published in the Journal of Pediatric Psychology, Eric Zhou, PhD, highlights Dana-Farber/Boston Children's Cancer and Blood Disorders Center's new "Sleep ALL Night" program, which aims to help children with leukemia sleep better during treatment. Read more: bit.ly/47NOhO0
Back in 2014, there were no targeted therapies approved for childhood brain cancers. Now there are a few, with more on the radar – almost all of which have deep roots in our science. Learn more about how our research is advancing treatment for childhood brain cancer: bit.ly/47hUQZd
October 31, 2025 at 2:00 PM
Back in 2014, there were no targeted therapies approved for childhood brain cancers. Now there are a few, with more on the radar – almost all of which have deep roots in our science. Learn more about how our research is advancing treatment for childhood brain cancer: bit.ly/47hUQZd
Please join us for a webinar on What to Know About Lung Cancer.
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
October 30, 2025 at 1:30 PM
Please join us for a webinar on What to Know About Lung Cancer.
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
Reposted by Dana-Farber Cancer Institute
Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer.
➡️ bit.ly/3JxnaO5
➡️ bit.ly/3JxnaO5
October 29, 2025 at 11:15 PM
Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer.
➡️ bit.ly/3JxnaO5
➡️ bit.ly/3JxnaO5
Reposted by Dana-Farber Cancer Institute
Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion.
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
October 28, 2025 at 2:48 PM
Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion.
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
We're proud to be included in Becker's 100 hospitals and health systems with great oncology programs 2025 list. Learn more and view the full list here: bit.ly/3Wn6yvj
100 hospitals and health systems with great oncology progra…
Becker’s Healthcare is proud to unveil its 2025 list of hospitals and health systems recognized for excellence in oncology. These leading institutions…
bit.ly
October 25, 2025 at 12:00 PM
We're proud to be included in Becker's 100 hospitals and health systems with great oncology programs 2025 list. Learn more and view the full list here: bit.ly/3Wn6yvj
Reposted by Dana-Farber Cancer Institute
New research in @natgenet.nature.com from @danafarber.bsky.social’s @ckadoch.bsky.social and Jessica St. Laurent, MD, uncovers potential targeted therapy for endometrial cancer.
bit.ly/3Jq2Yxv
bit.ly/3Jq2Yxv
October 21, 2025 at 7:35 PM
New research in @natgenet.nature.com from @danafarber.bsky.social’s @ckadoch.bsky.social and Jessica St. Laurent, MD, uncovers potential targeted therapy for endometrial cancer.
bit.ly/3Jq2Yxv
bit.ly/3Jq2Yxv